In the claims:

Claim 1 (currently amended) A nutraceutical or pharmaceutical compositions rich in unsaturated fatty acids, characterized in that they wherein it contains free or combined α-linolenic acid at a concentration ranging from 70 to 90% of the global weight, admixed with fatty acids having five and/or six double-bonds, in the form of capsules, granules, powder on a powdery carrier or of drinkable emulsions.

Claim 2 (currently amended) A neutraceutical or pharmaceutical compositions according to of Claim 1, in which wherein the α -linolenic acid is present as the free acid, an α -linolenic acid salt or an α -linolenic acid glyceride.

Claim 3 (currently amended) A neutraceutical or pharmaceutical compositions according to of Claim 1 or 2, in which wherein α-linolenic acid is present as an adsorbate in a cellulose derivative or in a cyclodextrine.

Claim 4 (currently amended) A neutraceutical or pharmaceutical compositions according to any of the preceding Claims 1 or 2, in which wherein the fatty acid with five double-bonds is eicosapentaenoic acid.

Claim 5 (currently amended)

A neutraceutical or pharmaceutical compositions according to any of Claims 1 to 3, in which wherein the fatty acid with six double-bonds is docosahexaenoic acid.

Claim 6 (currently amended)

A neutraceutical or pharmaceutical compositions according to of Claim 4, in which wherein the fatty acid with five double-bonds is present as a fish oil, selected among from the group consisting of halibut oil, cod liver oil, haddock oil, tuna oil, sardine oil and shark oil.

Claim 7 (currently amended) A neutraceutical or pharmaceutical compositions according to of Claim 5, in which wherein the six double-bond fatty acid is present as a fish oil, selected among from tuna oil and sardine oil.

Claim 8 (currently amended) \underline{A} neutraceutical or pharmaceutical compositions according to any of the preceding Claims 1, in which wherein α -linolenic acid is present as an oil rich or concentrated in α -linolenic acid.

Claim 9 (currently amended) \underline{A} neutraceutical or pharmaceutical compositions according to any of the preceding Claims $\underline{1}$, in which wherein α -linolenic acid is present as kiwi seed oil.

Claim 10 (currently amended) A neutraceutical or pharmaceutical compositions according to any of the preceding Claims 1, in which wherein eicosapentaenoic acid constitutes from 10 to 20% of the global weight.

Claim 11 (currently amended) A neutraceutical or pharmaceutical compositions according to any of the preceding Claims 1, in which wherein docosahexaenoic acid constitutes from 25 to 35% of the global weight.

Claim 12 (currently amended) A neutraceutical or pharmaceutical compositions according to any of the preceding Claims 1, which also contains some γ -linolenic acid

Claim 13 (currently amended) A neutraceutical or pharmaceutical compositions according to any of Claims 1 to 12, containing from 800 to 1000 mg of α-linolenic acid, from 80 to 120 mg of eicosapentaenoic and from 250 to 300 mg of docosahexaenoic acid, in the form of capsules, granules, powder on a powdery carrier or drinkable emulsions.

Claim 14 (currently amended) A neutraceutical or pharmaceutical compositions according to any of the preceding Claims 1, in which wherein the excipient or vehicle is a neutral oil, stable towards rancidity, selected among from the group consisting of almond oil, peanut oil, cotton seed oil, corn oil, water mixed with polysorbate of and a mix water/ethanol mixed with polyethyleneglycol stearate.

Claim 15 (currently amended) A neutraceutical or pharmaceutical compositions according to any of the preceding Claims 1, in the form of capsules, granules, powder on a powdery carrier or drinkable emulsions.

Claim 16 (currently amended) \underline{A} neutraceutical or pharmaceutical compositions according to any of the preceding Claims $\underline{1}$, characterized in that they wherein it contains about 115 mg of γ -linolenic acid, dispersed in an oil stable towards rancidity.